Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with...
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results
About this item
Full title
Author / Creator
Publisher
England: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
England: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term study.
We have recently reported that switch from bosentan to macitentan significantly improved exercise capacity in children and yo...
Alternative Titles
Full title
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2577687752
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2577687752
Other Identifiers
ISSN
1047-9511
E-ISSN
1467-1107
DOI
10.1017/S1047951120000773
